Salsalate for T1D Neuropathy: Phase 2 Trial Results
June 21, 2024
-
1 min
A study presented at the American Diabetes Association Scientific Sessions evaluated the use of salsalate, an NFkB blocker, as a potential treatment for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in type 1 diabetes. The 12-month phase 2/3 randomized trial compared salsalate with a placebo, showing no significant differences in the primary outcome but trends in nerve function improvements in secondary measures. Larger trials are needed to further evaluate salsalate's effects on type 1 diabetes neuropathy.
1. Study evaluated salsalate for diabetic neuropathy in type 1 diabetes. 2. The trial showed no significant differences in the primary outcome. 3. Trends in nerve function improvements were observed in secondary measures. 4. Larger trials are needed to further evaluate salsalate's effects. 5. One investigator disclosed multiple associations with organizations and pharmaceutical companies.
Listen Tab content
